Liquidia Corporation - LQDA STOCK NEWS

Liquidia Corporation (LQDA) announced it will report its full-year 2021 financial results on March 17, 2022. A conference call is scheduled for 8:30 a.m. ET to discuss these results and provide a corporate update. The call can be accessed via phone and will also be available for live streaming on Liquidia's website. The company specializes in biopharmaceuticals, particularly treatments for pulmonary hypertension, and has received tentative FDA approval for its product YUTREPIA™ (treprostinil) inhalation powder.

Pathalys Pharma, a late-stage biopharmaceutical company, has been established with seed financing from DaVita Venture Group and Catalys Pacific. The company focuses on chronic kidney disease (CKD) treatments, starting with the investigational drug upacicalcet, which has demonstrated efficacy in Japan. Pathalys plans to conduct two phase 3 clinical trials in the U.S. for upacicalcet to treat secondary hyperparathyroidism in hemodialysis patients. Neal Fowler, a former CEO at Liquidia, has been appointed as CEO, enhancing the leadership team's industry experience.

Liquidia Corporation (NASDAQ: LQDA) announced the grant of an inducement stock option for 25,700 shares of its common stock to a new non-executive employee. This grant, made under the 2022 Inducement Plan, serves as a key part of the employee's compensation package. The stock option is exercisable at a price of $5.47 per share, matching the closing price on the grant date, February 22, 2022. It features a ten-year term and vests over four years with specific vesting conditions.

Liquidia Corporation (NASDAQ: LQDA) has secured a new debt facility with Silicon Valley Bank (SVB) amounting to up to $40 million, announced on January 7, 2022. The initial $20 million has been funded, allowing Liquidia to retire existing debt and add $9.5 million to its cash reserves. Future tranches are contingent on regulatory milestones related to its product YUTREPIA™. The debt facility will mature by December 1, 2025, with interest-only payments through December 2023. This capital aims to support pre-commercial activities and the anticipated launch of YUTREPIA.

Liquidia Corporation (NASDAQ: LQDA) appointed Dr. Roger Jeffs as CEO, effective January 3, 2022. He succeeds Damian deGoa, who will remain on the board until January 31, 2022. Dr. Jeffs, who has extensive experience in drug development, aims to optimize the upcoming launch of YUTREPIA™ (treprostinil) inhalation powder, which recently received tentative FDA approval. The company focuses on pulmonary arterial hypertension and plans to leverage its PRINT® Technology for future developments. This leadership change comes as Liquidia prepares for potential profitability with YUTREPIA's launch.

Liquidia Corporation (LQDA) announced a partial judgment in its favor regarding U.S. Patent No. 9,604,901 in ongoing litigation with United Therapeutics Corporation (UTC) under the Hatch-Waxman Act. The court's decision acknowledged Liquidia’s non-infringement of the patent, while UTC retains appellate rights. This ruling allows the ongoing regulatory stay of YUTREPIA™ (treprostinil) inhalation powder approval by the FDA to continue under U.S. Patent No. 9,593,066. The trial is scheduled for March 28-30, 2022.

Liquidia Corporation (NASDAQ: LQDA) has announced that its Chief Financial Officer, Michael Kaseta, will speak at the Jefferies 2021 Virtual London Healthcare Conference from November 16-19, 2021. The insightful fireside chat will be available on-demand from 8:00 a.m. GMT on November 18, 2021, for registered participants. Investors can access the webcast on Liquidia's website, which will remain archived for 30 days post-event. Liquidia focuses on the development of innovative therapies for pulmonary hypertension, including YUTREPIA™, an inhalation powder treatment.

Liquidia Corporation (NASDAQ: LQDA) announced the FDA granted tentative approval for YUTREPIA™ (treprostinil) inhalation powder, intended for treating pulmonary arterial hypertension (PAH). This approval, which confirms YUTREPIA's compliance with safety, quality, and efficacy standards, is a pivotal step toward market introduction. However, final approval awaits the resolution of ongoing litigation with United Therapeutics, impacting the commercial launch timeline, potentially slated for October 2022. YUTREPIA aims to provide a user-friendly alternative to existing therapies, targeting a significant market with sales exceeding $480 million.

Liquidia Corporation (LQDA) reported Q3 2021 financial results, highlighting a rise in Treprostinil Injection adoption among patients and payers, which doubled the patient count since May 2021. Revenue for Q3 was $3.2 million, compared to zero in Q3 2020, driven by a promotion agreement with Sandoz. However, revenue was impacted by a reduction in profit split percentage. The net loss decreased to $7.3 million, or $0.14 per share, from $15.0 million in Q3 2020. The FDA completed pre-approval inspections for LIQ861, with a decision expected by November 7, 2021.